Viatris Inc., in collaboration with Medicines for Europe, has published the results of an independent study analyzing the off-patent medicines market in Europe, with a particular focus on antibiotics. The study found that between 2020 and 2024, the average price of the ten most widely used off-patent antibiotics dropped by 10.4%, despite significant increases in production costs and inflation. The analysis highlights the growing challenge of ensuring patient access to essential medicines amid price pressures and supply shortages. Viatris and Medicines for Europe are urging policymakers and healthcare leaders to reform national pricing and procurement systems to safeguard the availability of vital antibiotics and strengthen sustainable access to off-patent medicines.